Long-term persistence with secukinumab in patients with moderate-to-severe psoriasis
Farmacia Hospitalaria · 2025
DOI: 10.1016/j.farma.2024.10.017 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Farmacia Hospitalaria, 2025. Verfasst von Joaquín Borrás-Blasco und 4 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Farmacia, Hospital de Sagunto, Valencia, Spain. Electronic address: jborrasb@gmail.com. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
OBJECTIVE: The aim of this study was to evaluate the real-world persistence, effectiveness, and safety of secukinumab in adult patients with moderate-to-severe psoriasis in two different hospitals. METHODS: Retrospective cohort study that used registries and medical records from 2 different hospitals (February 2015-March 2024). Adults with moderate-to-severe psoriasis who initiated secukinumab treatment were identified and followed-up until March 2024, or disenrollment. Baseline demographic and clinical characteristics studied included sex, age at diagnosis, weight, prior failed treatments, duration of treatment and psoriasis area severity index (PASI) score. Adherence was measured using medication possession ratio (MPR); patients with MPR ≥ 80% were considered adherent. Persistence, effectiveness, safety, and dosage regimen of secukinumab were collected. Kaplan-Meier analysis was used to estimate secukinumab persistence using 1-year intervals. RESULTS: A total of 88 patients with moderate-to-severe psoriasis were included, of whom 45 (51.1%) had not received prior biological treatment. Baseline PASI score was 15.0 ± 2.9 and patients received 1.4 ± 0.8 prior biological treatments. The most common previous biological treatments included anti-TNFα (60.5%) and ustekinumab (20.9%). 34 (38.6%) patients discontinued secukinumab treatment due to the following reasons. 19 (21.5%) due to a lack of effectiveness, 8 (9.2%), due to achieve only a partial response, and 7 (7.9%) due to adverse effects. Secukinumab persistence was 61.5 ± [21.7] months for all patients. When performing a subgroup analysis, non-naïve patients obtained a persistence of 63.5 ± [12.4] months followed by 54.1 ± [14.8] months for naïve patients (p = .804). Secukinumab persistence at 1 year, 2 years, and 3 years was 72.7%, 51.1%, and 39.8%, respectively. CONCLUSIONS: Secukinumab demonstrated persistence in more than 70% of patients with moderate to severe psoriasis after the first year of treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Farmacia, Hospital de Sagunto, Valencia, Spain. Electronic address: jborrasb@gmail.com.
- Servicio de Farmacia, Hospital de Sagunto, Valencia, Spain.
- Servicio de Farmacia, Hospital de Alzira, Alzira, Spain.
- Servicio de Dermatología, Hospital de Sagunto, Valencia, Spain.
Zitieren
APA
Borrás-Blasco, J., Cornejo, S., Valcuende-Rosique, A., Alcala, R., & Bono, A. N. (2025). Long-term persistence with secukinumab in patients with moderate-to-severe psoriasis. Farmacia Hospitalaria. https://doi.org/10.1016/j.farma.2024.10.017
Vancouver
Borrás-Blasco J, Cornejo S, Valcuende-Rosique A, Alcala R, Bono AN. Long-term persistence with secukinumab in patients with moderate-to-severe psoriasis. Farmacia Hospitalaria. 2025. doi:10.1016/j.farma.2024.10.017
BibTeX
@article{BorrsBlasco2025,
author = {Borrás-Blasco, Joaquín and Cornejo, Silvia and Valcuende-Rosique, Alejandro and Alcala, Rebeca and Bono, Ana Navalon},
title = {Long-term persistence with secukinumab in patients with moderate-to-severe psoriasis},
journal = {Farmacia Hospitalaria},
year = {2025},
doi = {10.1016/j.farma.2024.10.017}
}
EUVIMED